September 2, 2025 — Leads & Copy — Enveric Biosciences (NASDAQ: ENVB) has relocated its corporate headquarters to Cambridge, Massachusetts, according to a recent announcement. The biotechnology company aims to advance next-generation neuroplastogenic small molecules for psychiatric and neurological disorders.
Enveric anticipates that the move will strengthen collaborations, facilitate talent recruitment, and enhance visibility within the life sciences cluster. The company’s lead molecule, EB-003, is designed to deliver therapeutic benefits while minimizing hallucinatory effects and is advancing toward clinical trials.
According to Joseph Tucker, Ph.D., Director and CEO of Enveric, the relocation represents an important step in Enveric’s growth trajectory and provides unparalleled access to scientific innovation, industry leadership, and capital markets.
Enveric Biosciences (NASDAQ: ENVB) is focused on developing neuroplastogenic therapeutics for unmet needs in psychiatric and neurological disorders. Enveric’s lead candidate, EB-003, is designed to selectively engage both 5-HT₂A and 5-HT₁B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.
For more information, please visit www.enveric.com.
Contact:
Joseph Tucker, Ph.D., Director and CEO of Enveric.
Source: Enveric Biosciences
